The global market for Syringes is projected to exceed US$20.9 billion by 2024, driven by growing healthcare burden compounded by aging population and rise of chronic and infectious diseases, and the ensuing increase in interventional care involving surgeries and needle stick procedures.
Syringes are widely used in hospitals, in immunization programs, in intravenous drug usage and in daily insulin by people with diabetes. Development of new drugs and demographic factors such as an aging population requiring intensive healthcare continues to drive the demand for syringes. Other factors driving growth include increasing prevalence of chronic and infectious diseases that require intravenous administration of drugs, increasing use of biological drugs, and government regulations focused on patient and healthcare worker safety. Demand for safety syringes continues to expand amidst growing emphasis on safety to avoid risk of cross-contamination and transmission of bloodborne pathogens. The need for pain-free administration of injections, and regulations dictating practices in healthcare work environment among others contribute to the development of safety syringes. Another factor driving demand is the difficulty encountered in the disposal of conventional needle syringes. A large and growing number of insulin dependent diabetics propel the insulin syringe market.
Design and recommendations for safety syringes have evolved over the years beginning with AD syringes for immunization programs and advancing to syringes with re-use prevention design and sharps injury protection features. Other advancements include introduction of metal-free syringes. Ongoing research in the pain free syringes space is to allow injections without pain, with smaller needles. Hypodermic syringes represent the largest product market. Demand for prefilled syringes for self-administration is on the rise supported by increased use of biologic and injectable drugs, growing elderly population, rise in self-administered injections, and increasing incidences of chronic diseases that require accurate and high dosing. Due to the growing use of self-injection systems, which are combination products, human factors are playing a major role in the design of self-injection systems, so as to limit any risk of user mishandling.
The United States represents the largest market worldwide. Asia-Pacific is forecast to witness the fastest growth with a CAGR of 9.0% over the analysis period driven by factors such as growing focus on patient-oriented care, expansion of healthcare services in public as well as private sectors, and active adoption of various national-level disease control projects
Major players in the market include Abbott Laboratories Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, Cardinal Health, Kawamoto Corporation, Medline Industries Inc., Merit Medical Systems, Nipro Medical Corporation Retractable Technologies, Smiths Medical, and Terumo Corporation among others.